Quantinno Capital Management LP Has $90.64 Million Stock Holdings in HCA Healthcare, Inc. $HCA

Quantinno Capital Management LP raised its position in HCA Healthcare, Inc. (NYSE:HCA) by 17.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 191,541 shares of the company’s stock after buying an additional 27,838 shares during the quarter. Quantinno Capital Management LP’s holdings in HCA Healthcare were worth $90,645,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Lazard Asset Management LLC lifted its stake in HCA Healthcare by 20.5% in the 1st quarter. Lazard Asset Management LLC now owns 307,343 shares of the company’s stock valued at $145,447,000 after purchasing an additional 52,362 shares during the last quarter. Intelligence Driven Advisers LLC increased its holdings in HCA Healthcare by 8.1% in the first quarter. Intelligence Driven Advisers LLC now owns 651 shares of the company’s stock valued at $308,000 after purchasing an additional 49 shares during the period. OMERS ADMINISTRATION Corp grew its position in shares of HCA Healthcare by 17.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 14,997 shares of the company’s stock valued at $7,097,000 after buying an additional 2,263 shares during the last quarter. Lombard Odier Asset Management Switzerland SA bought a new position in HCA Healthcare during the 1st quarter worth approximately $1,910,000. Finally, Matrix Private Capital Group LLC acquired a new stake in HCA Healthcare during the 1st quarter worth about $282,000. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $389.74 on Tuesday. The firm has a fifty day moving average price of $386.30 and a two-hundred day moving average price of $452.90. HCA Healthcare, Inc. has a one year low of $331.61 and a one year high of $556.52. The company has a market cap of $86.46 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 1.29 and a beta of 1.12.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The firm had revenue of $20.23 billion during the quarter, compared to the consensus estimate of $19.76 billion. During the same quarter last year, the company posted $6.84 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. Equities research analysts expect that HCA Healthcare, Inc. will post 29.19 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be paid a $0.78 dividend. This represents a $3.12 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, September 16th. HCA Healthcare’s dividend payout ratio is currently 10.45%.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. HCA reported adjusted earnings of $7.59 per share versus the $7.56 consensus estimate, while revenue rose 8.7% year over year to $20.23 billion, topping forecasts of $19.76 billion. The earnings beat and continued revenue growth are supporting investor sentiment. HCA Healthcare’s Q2 CY2026 sales top estimates
• Positive Sentiment: Analysts remain broadly constructive despite lower targets. Truist, Oppenheimer and KeyCorp cut their price targets but retained buy, outperform or overweight ratings. RBC also reaffirmed its outperform rating with a $435 target, indicating that analysts still see upside from current levels. HCA Healthcare Analysts Slash Their Forecasts After Q2 Results
• Neutral Sentiment: HCA declared a quarterly dividend of $0.78 per share. The dividend is payable September 30 to shareholders of record September 16 and carries an indicated yield of approximately 0.8%, providing modest shareholder income.
• Neutral Sentiment: Leadership change at two Tampa hospitals. HCA promoted a new chief executive officer for the facilities, a routine management update with limited immediate financial impact. HCA promotes new CEO of 2 Tampa hospitals
• Negative Sentiment: Uninsured Affordable Care Act patients are a concern. Nearly all of HCA’s ACA exchange patients reportedly lacked insurance coverage during the quarter, highlighting reimbursement and bad-debt risks that could weigh on margins and future earnings.
• Negative Sentiment: Multiple analysts reduced their forecasts after the earnings release. Barclays moved to equal weight with a $387 target, while Baird maintained a neutral rating and lowered its target to $393. The widespread target reductions suggest expectations for HCA’s future growth and profitability have moderated.
• Negative Sentiment: Mission Health compliance concerns remain unresolved. Reports of a third consecutive year of compliance issues add legal, regulatory and reputational risk for HCA. HCA Healthcare faces third straight year of Mission Health compliance concerns

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HCA shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of HCA Healthcare in a research report on Wednesday, July 15th. Barclays cut their price objective on shares of HCA Healthcare from $402.00 to $387.00 and set an “equal weight” rating on the stock in a research report on Monday. Wall Street Zen downgraded HCA Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. TD Cowen decreased their target price on shares of HCA Healthcare from $500.00 to $431.00 and set a “buy” rating for the company in a research report on Monday, June 22nd. Finally, Argus cut their target price on HCA Healthcare from $560.00 to $500.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Fourteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $473.36.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.